Use of cannabis and its products among patients in a tertiary epilepsy center: A cross-sectional survey

被引:4
作者
Puteikis, Kristijonas [1 ]
Mameniskiene, Ruta [2 ]
机构
[1] Vilnius Univ, Fac Med, Vilnius, Lithuania
[2] Vilnius Univ, Ctr Neurol, Santariskiu G 2, LT-08661 Vilnius, Lithuania
关键词
Antiepileptic drugs; Attitudes; Cannabis; Cannabidiol; Epilepsy; MARIJUANA USE; SEIZURES; ACCURACY;
D O I
10.1016/j.yebeh.2020.107214
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Purpose: The purpose of this study was to evaluate whether the topic of using cannabis as a treatment option for epilepsy is relevant among adult patients with the disorder and assess the possible determinant attitudes for having a history of cannabis consumption or being inclined to try it for medical purposes. Material and methods: Willing adult (>= 18 years) patients with diagnosed epilepsy participated in a cross-sectional survey study at a tertiary epilepsy center. The questions were related to cannabis use and opinions towards the safety and efficacy profile of cannabis for treating epilepsy. Results: From 250 respondents, 41 (16.4%) reported prior use of cannabis or its preparations (15 [36.6%] for self-treatment). There were 81 (32.4%) participants further interested in cannabis use for treating epilepsy. In a binary regression model (Nagelkerke <(R-2)over bar> = 0331), the opinion that cannabis is safer because of its natural origin (beta = 0.749, p = 0.027) and the premise of understanding its legal status (beta = 0.418, p = 0.024) positively predicted which participants have reported cannabis use. These patients were also more likely to consult internet sources (p = 0.004) and agree that cannabis as an epilepsy treatment option is effective (U = 2231.5, p < 0.001), safe (U = 1822.0, p < 0.001) and has no side effects (U = 2470.5, p = 0.004). Patients who had not tried cannabis were more likely to envision the products as potentially addictive (p = 0.012) and presumably be deterred from using them due to beliefs in harmful effects (beta = - 0.632, p = 0.025). In general, nonusers were not inclined to try cannabis for treating epilepsy (Md = 2, range 1 to 7). However, those interested in the possibility of using cannabis to treat epilepsy would be more willing to try the respective preparations (p < 0.001). Conclusion: Among adult patients with epilepsy, we report no particularly high rate of cannabis use or interest in applying cannabis for medical purposes. In order to clarify the scientific and legal status of the preparations, treating neurologists should consult prior users and patients interested in the possibility of trying cannabis as an epilepsy remedy. (C) 2020 Elsevier Inc All rights reserved.
引用
收藏
页数:5
相关论文
共 36 条
  • [1] Adverse effects of cannabinoids
    Anciones, Carla
    Gil-Nagel, Antonio
    [J]. EPILEPTIC DISORDERS, 2020, 22 : S29 - S32
  • [2] Epilepsy and cannabidiol: a guide to treatment
    Arzimanoglou, Alexis
    Brandi, Ulrich
    Cross, J. Helen
    Gil-Nagel, Antonio
    Lagae, Lieven
    Landmark, Cecilie Johannessen
    Specchio, Nicola
    Nabbout, Rima
    Thiele, Elizabeth A.
    Gubbay, Oliver
    [J]. EPILEPTIC DISORDERS, 2020, 22 (01) : 1 - 14
  • [3] Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development
    Bialer, Meir
    Johannessen, Svein I.
    Koepp, Matthias J.
    Levy, Rene H.
    Perucca, Emilio
    Tomson, Torbjorn
    White, H. Steve
    [J]. EPILEPSIA, 2018, 59 (10) : 1842 - 1866
  • [4] Labeling Accuracy of Cannabidiol Extracts Sold Online
    Bonn-Miller, Marcel O.
    Loflin, Mallory J. E.
    Thomas, Brian F.
    Marcu, Jahan P.
    Hyke, Travis
    Vandrey, Ryan
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (17): : 1708 - 1709
  • [5] What has been the impact of new drug treatments on epilepsy?
    Chen, Zhibin
    Brodie, Martin J.
    Kwan, Patrick
    [J]. CURRENT OPINION IN NEUROLOGY, 2020, 33 (02) : 185 - 190
  • [6] Cannabinoids and the expanded endocannabinoid system in neurological disorders
    Cristino, Luigia
    Bisogno, Tiziana
    Di Marzo, Vincenzo
    [J]. NATURE REVIEWS NEUROLOGY, 2020, 16 (01) : 9 - 29
  • [7] A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?
    Cross, J. Helen
    Cock, Hannah
    [J]. NEUROPHARMACOLOGY, 2020, 170
  • [8] Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
    Devinsky, Orrin
    Patel, Anup D.
    Cross, J. Helen
    Villanueva, Vicente
    Wirrell, Elaine C.
    Privitera, Michael
    Greenwood, Sam M.
    Roberts, Claire
    Checketts, Daniel
    VanLandingham, Kevan E.
    Zuberi, Sameer M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (20) : 1888 - 1897
  • [9] Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
    Devinsky, Orrin
    Cross, J. Helen
    Laux, Linda
    Marsh, Eric
    Miller, Ian
    Nabbout, Rima
    Scheffer, Ingrid E.
    Thiele, Elizabeth A.
    Wright, Stephen
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (21) : 2011 - 2020
  • [10] European Monitoring Centre for Drugs and Drug Addiction, 2019, EUR DRUG REP, DOI [10.2810/576732, DOI 10.2810/576732]